trending Market Intelligence /marketintelligence/en/news-insights/trending/ttAH4JTWzDA3fFefH3OZuw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Tokyo's Astellas Pharma acquires I-O company Xyphos Biosciences

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Tokyo's Astellas Pharma acquires I-O company Xyphos Biosciences

Astellas Pharma Inc. acquired Xyphos Biosciences Inc., a privately held biotechnology company developing immune therapies for cancer.

Tokyo's Astellas paid $120 million upon closing of the deal. Considering potential milestone payments, the total value of the transaction is $665 million.

Under the deal, South San Francisco, Calif.-based Xyphos became a wholly owned unit of Astellas. The Japanese drugmaker also gained Xyphos' proprietary technology platform, called ACCEL, which allows for ways to mobilize and control immune cells to destroy targets, such as tumor cells.

Astellas said the deal is in line with its immuno-oncology strategy. "Combining this technology with our capabilities in cell therapy that we have been working on so far, we can create next-generation high-function cells and maximize the value of our technology," the drugmaker said in a news release.